Jérusalem

BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, March 24, 2021

For the three months ended December 31, 2020, revenues were $7.1 million, a 17% increase sequentially from the third quarter of 2020, and a 12% increase from the fourth quarter of 2019.

Key Points: 
  • For the three months ended December 31, 2020, revenues were $7.1 million, a 17% increase sequentially from the third quarter of 2020, and a 12% increase from the fourth quarter of 2019.
  • As of December 31, 2020, BrainsWays Deep TMS installed base was 629 total systems, a 19% increase compared to prior year results.
  • Total revenues for the fourth quarter of 2020 were $7.1 million, compared with $6.0 million in the third quarter of 2020, and $6.3 million in the fourth quarter of 2019, increases of 17% and 12%, respectively.
  • Operating expenses for the fourth quarter totaled $5.9 million, compared with $6.8 million for the fourth quarter of 2019.

Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020

Retrieved on: 
Thursday, March 18, 2021
Health sciences, Distributed computing, Entera, Middleware, Health, Clinical trial, Pharmacology

Enrollment in the Phase 2 clinical trial in Israel was completed in November 2020 with 161 subjects.

Key Points: 
  • Enrollment in the Phase 2 clinical trial in Israel was completed in November 2020 with 161 subjects.
  • Operating expenses were $11.3 million for the year ended December 31, 2020, compared to $11.5 million for the year ended December 31, 2019.
  • Enteras operating loss was $(11.1) million for the year ended December 31, 2020, compared to $(11.5) million for the year ended December 31, of 2019.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021

Retrieved on: 
Thursday, March 11, 2021
Distributed computing, Entera, Middleware, Amgen, NASDAQ, Life sciences, Companies, Economy of the United States

BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, before the U.S. financial markets open.

Key Points: 
  • BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, before the U.S. financial markets open.
  • Enteras management will host a conference call on Thursday, March 18, 2021 at 8:30 a.m. EDT to discuss the results for the quarter.
  • To access a live audio webcast of the presentation on the Investor Relations page of Enteras website, please click here .
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com .

Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Musculoskeletal system, Skeletal system, Biology, Osteocalcin, Bone resorption, Bone, Osteoblast, Resorption, Osteoclast, Medication-related osteonecrosis of the jaw

Similar to P1NP, Osteocalcin is a biomarker for bone formation by osteoblasts, the cells that build new bone.

Key Points: 
  • Similar to P1NP, Osteocalcin is a biomarker for bone formation by osteoblasts, the cells that build new bone.
  • CTX is a biomarker that indicates the rate of bone resorption by osteoclasts, the cells that remove old bone.
  • Biomarker data from the Placebo and EB613 2.5mg dose group are summarized below:
    Study Medication, EB613 or placebo, was generally well tolerated through 3 months of treatment.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Entera Bio To Present At The H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021
Distributed computing, Entera, Middleware, Amgen, NASDAQ, Life sciences, Companies, Economy of the United States

BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate in the H.C. Wainwright Global Life Sciences Conference.

Key Points: 
  • BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate in the H.C. Wainwright Global Life Sciences Conference.
  • As part of the virtual conference, which is being held March 9-10, 2021, Spiros Jamas, Enteras Chief Executive Officer will present an overview of the Company's business.
  • A webcast of the presentation will be available starting on March 9 at 7 a.m.
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com .

BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Retrieved on: 
Monday, March 1, 2021
Financial markets, U.S. Securities and Exchange Commission, Stock market, SEC filings, Initial public offering, Prospectus, Registration statement, Security, ADSS, Corporate finance, Finance, United States securities law

The gross proceeds to BrainsWay from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $45.2 million.

Key Points: 
  • The gross proceeds to BrainsWay from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $45.2 million.
  • The ADSs were offered pursuant to a "shelf" registration statement on Form F-3 (File No.
  • 333-248601), including a base prospectus, that was previously filed by BrainsWay and as was declared effective by the Securities and Exchange Commission (the SEC) on October 16, 2020.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov .

Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research

Retrieved on: 
Thursday, February 25, 2021
Clinical pharmacology, Clinical research, Pharmaceutical industry, Tolerability, Adverse event

The Phase 2a study demonstrated the safety and tolerability of EB612 administered four times daily for 16 weeks to patients with HypoPT.

Key Points: 
  • The Phase 2a study demonstrated the safety and tolerability of EB612 administered four times daily for 16 weeks to patients with HypoPT.
  • No drug-related serious adverse events were reported and most of the adverse events were not considered study drug-related.
  • The publication of our Phase 2a EB612 study results in this leading peer-reviewed journal support our HypoPT development program and the value of our platform technology.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Financial markets, Neuroscience, Depositary receipts, Equity securities, Brainsway, Neurophysiology, Neuropsychology, Treatment of depression, American depositary receipt, Tel Aviv Stock Exchange

CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced it has priced an underwritten public offering of4,622,000 American Depositary Shares, each representing two ordinary shares, at an offering price of$8.50 per American Depositary Share.

Key Points: 
  • CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced it has priced an underwritten public offering of4,622,000 American Depositary Shares, each representing two ordinary shares, at an offering price of$8.50 per American Depositary Share.
  • The gross proceeds from the offering will be approximately $39,287,000, before deducting underwriting discounts and commissions and estimated offering expenses.
  • BrainsWay has also granted the underwriters a 30-day option to purchase up to an additional693,300 American Depositary Shares on the same terms and conditions.
  • The closing of the offering is expected to take place on February 25, 2021, subject to the satisfaction of customary closing conditions.

BrainsWay Ltd. Announces Proposed Public Offering of American Depositary Shares

Retrieved on: 
Monday, February 22, 2021
Financial markets, Finance, Corporate finance, Initial public offering, Depositary receipts, Equity securities, American depositary receipt, Brainsway, Prospectus, Tel Aviv Stock Exchange, Public offering

CRESSKILL, N.J. and JERUSALEM, Feb. 22, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd.(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it intends to offer American Depositary Shares, each representing two ordinary shares, in an underwritten public offering.BrainsWay also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the American Depositary Shares sold in the offering.

Key Points: 
  • CRESSKILL, N.J. and JERUSALEM, Feb. 22, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd.(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it intends to offer American Depositary Shares, each representing two ordinary shares, in an underwritten public offering.BrainsWay also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the American Depositary Shares sold in the offering.
  • All of the American Depositary Shares, and the underlying ordinary shares, will be offered byBrainsWay.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The offering of the American Depositary Shares will be made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Neuroscience, Brainsway, Neurophysiology, Neuropsychology, Neurotechnology, Treatment of depression, Tel Aviv Stock Exchange, Tase, Hackett

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced the addition of Fran Hackett as Vice President of North American Sales effective February 16, 2021.

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced the addition of Fran Hackett as Vice President of North American Sales effective February 16, 2021.
  • As a veteran sales leader with a robust background across varied medical markets, Frans addition will be critical to this phase of the Companys growth, said Hadar Levy, Senior Vice President and General Manager of BrainsWay.
  • He has been instrumental in building industry-leading teams, and I am excited to have him take over our commercial efforts in North America.
  • Mr. Hackett brings more than 30 years of domestic and international sales, business development, and executive leadership to BrainsWay.